Procognia

Now available!

Kinome 2.0^plus compound profiling kits

Same day selectivity and potency studies for 160 - 200 kinases. Increase the number of kinases within screening programs without increasing the budget. Profiling in less than a day with lower costs per data point.

How it works	Support
Applications	Your needs
Drug screening

Procognia is helping to develop a fuller understanding of proteins as drug targets and biomarkers. Utilising technologies based around protein arrays, we provide both the means for unraveling disease mechanisms, biomarker discovery and selection and monitoring of individuals recruited into clinical trials. Our protein function arrays products and technologies are improving the productivity of protein science.

Based on Procognia's proprietary tag technology, catalogue themed arrays of functional human proteins are available via Sigma Aldrich

find out more > sigma-aldrich.com

Procognia Israel offers a state-of-the-art platform for glycoanalysis, for improving biopharmaceutical development and manufacturing, and for life science research. For more information, please visit us at http://www.procognia-il.com.

Biotechnology Company Procognia Israel Raised NIS 43 million in the Tel-Aviv Stock Exchange
press_release    other press releases

Procognia enters protein kinase array collaboration with GSK
press_release    other press releases

Teva and Procognia (Israel) Ltd. sign an exclusive collaboration agreement for the development of biopharmaceuticals
press_release    other press releases

Procognia’s U-c fingerprint technology to be used for rapid glycoanalysis at the Centre for Bioanalytical Sciences
press_release    other press releases

Procognia’s glycoanalysis poster wins “Best Poster” at the IBC BioProcess International Conference & Exhibition
more...

Procognia awarded 2005 Frost & Sullivan Competitive Strategy Leadership Award for success in providing innovative protein array technologies
press_release    other press_releases